Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
In this protocol, the investigators hypothesize that the combination of intravenous busulfan
and melphalan with carfilzomib will be an effective preparative regimen with acceptable
toxicity for participants with multiple myeloma who are candidates for autologous stem cell
transplantation. To test this hypothesis, the investigators designed a phase I/II trial
combining IV busulfan 130 mg/m2 plus melphalan 140 mg combined with escalating doses of
carfilzomib ranging from 20 mg/m2 to 45 mg/m2. These results will be compared with the
center's historical controls of participants treated with melphalan, busulfan and bortezomib.